{
  "id": 12432858,
  "title": "HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.",
  "url": "https://urgent.news/2026/10/06/hsbc-thinks-abbvie-can-climb-to-315-heres-the-bull-case-in-plain-12432858",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T17:35:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/hsbc-thinks-abbvie-can-climb-315-heres-bull-case-plain-english"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsOne analyst sees expanded uses for Rinvoq and Skyrizi propelling AbbVie stock to as much as $315 per share.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.",
        "url": "https://urgent.news/2026/10/06/hsbc-thinks-abbvie-can-climb-to-315-heres-the-bull-case-in-plain",
        "published": "2026-10-06T17:15:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}